Solexa acquired by Illumina for $600m in shares; to keep Cambridge ops

Illumina Inc will acquire Solexa Inc (SLXA) in an all share merger worth about $600m, the two Nasdaq-listed companies said in a joint statement overnight.

Illumina has also agreed to invest $50m in Solexa in exchange for newly issued Solexa shares.

Headquartered in Hayward, California, with substantial operations in Cambridge, Solexa has developed a next generation genetic analysis system for use in whole genome sequencing, targeted resequencing, digital gene expression and microRNA analysis.

Illumina, headquartered in San Diego, said it expects to maintain Solexa's operations in both California and Cambridge. Illumina develops and markets next-generation tools for the large-scale analysis of genetic variation and function.

Together, the companies said, they will create the only company with genome-scale technology for genotyping, gene expression and sequencing, the three cornerstones of modern genetic analysis.

The market opportunity in sequencing is estimated at $1 billion, creating a market opportunity for the combined company in excess of $2.25 billion.

Solexa CEO John West, who will join Illumina as Senior VP and General Manager of the Sequencing Business, said: "This transaction is expected to provide significant benefits to Solexa stockholders, customers and employees. I am very excited about the opportunity that Solexa's combination with Illumina presents.

“Illumina brings proven business systems, world-class sales and support infrastructure and significant experience in managing products poised for substantial growth. I expect these attributes will help rapidly deploy Solexa's next generation sequencing platform,” he said.

“Together we expect to reach and exceed the milestone of the $100,000 genome."

Solexa 3Q

Also overnight, Solexa reported third-quarter results in which sales were down 33% to $0.57m from $0.84m. The company posted an 8% narrower net loss of roughly $9.9m, compared to $10.8m.

Solexa’s share price rose roughly 30% to $12.57, compared to the offer price of $14 each.

Solexa was originally a spin out from the University of Cambridge and was based on inventions made by a group led by David Klenerman and Shankar Balasubramanian in the Department of Chemistry.

14th November 2006

Previous articles
Celsis cost control sees ’09 profit grow 22%
OrthoMimetics, CMI sign licence deal for tissue scalfolding technology to cut joint surgery
Clinical Cell Culture's CEO leaves after strategic review; costs cut
Acambis steps up R&D spending; aborts pursuit of 'major acquisition'
Xaar says 1H ’09 sales down on 1H’08 but improving
Alizyme raises £14.5m; appoints new CEO: shares gain 15%
ARM says pre-tax profit, revenue down slightly in 2Q; on track for FY08 revenue growth
Autonomy acquires records manager Meridio for £20m; reports strong 3Q07 growth
Dollar's slump a threat to Silicon Fen? Not yet
Xaar confirms stellar '05; sees good medium term growth
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Esprit Capital Partners


Robert Hook
Chairman


In August 2007 Draper Fisher Jurvetson acquired a strategic stake in Esprit Capital Partners, one of the largest and most experienced teams of technology venture capital investors in Europe. Esprit Capital Partners was created as Cazenove Private Equity merged with Prelude Ventures to establish a

[Esprit Capital Partners's profile]


Top20 Index




Currently: 161.56